184 related articles for article (PubMed ID: 10510359)
1. Deficiency of transporter for antigen presentation (TAP) in tumor cells allows evasion of immune surveillance and increases tumorigenesis.
Johnsen AK; Templeton DJ; Sy M; Harding CV
J Immunol; 1999 Oct; 163(8):4224-31. PubMed ID: 10510359
[TBL] [Abstract][Full Text] [Related]
2. Increased tumorigenicity, but unchanged immunogenicity, of transporter for antigen presentation 1-deficient tumors.
Qin Z; Harders C; Cao X; Huber C; Blankenstein T; Seliger B
Cancer Res; 2002 May; 62(10):2856-60. PubMed ID: 12019164
[TBL] [Abstract][Full Text] [Related]
3. Down-regulation of the MHC class I antigen-processing machinery after oncogenic transformation of murine fibroblasts.
Seliger B; Harders C; Lohmann S; Momburg F; Urlinger S; Tampé R; Huber C
Eur J Immunol; 1998 Jan; 28(1):122-33. PubMed ID: 9485192
[TBL] [Abstract][Full Text] [Related]
4. Furin-processed antigens targeted to the secretory route elicit functional TAP1-/-CD8+ T lymphocytes in vivo.
Medina F; Ramos M; Iborra S; de León P; Rodríguez-Castro M; Del Val M
J Immunol; 2009 Oct; 183(7):4639-47. PubMed ID: 19752221
[TBL] [Abstract][Full Text] [Related]
5. Impaired transporter associated with antigen processing (TAP) function attributable to a single amino acid alteration in the peptide TAP subunit TAP1.
Ritz U; Drexler I; Sutter D; Abele R; Huber C; Seliger B
J Immunol; 2003 Jan; 170(2):941-6. PubMed ID: 12517960
[TBL] [Abstract][Full Text] [Related]
6. Restoration of the expression of transports associated with antigen processing in human malignant melanoma increases tumor-specific immunity.
Tao J; Li Y; Liu YQ; Wang L; Yang J; Dong J; Wu Y; Shen GX; Tu YT
J Invest Dermatol; 2008 Aug; 128(8):1991-6. PubMed ID: 18385764
[TBL] [Abstract][Full Text] [Related]
7. Identification of sequences in the human peptide transporter subunit TAP1 required for transporter associated with antigen processing (TAP) function.
Ritz U; Momburg F; Pircher HP; Strand D; Huber C; Seliger B
Int Immunol; 2001 Jan; 13(1):31-41. PubMed ID: 11133832
[TBL] [Abstract][Full Text] [Related]
8. Correction of defects responsible for impaired Qa-2 class Ib MHC expression on melanoma cells protects mice from tumor growth.
Chiang EY; Henson M; Stroynowski I
J Immunol; 2003 May; 170(9):4515-23. PubMed ID: 12707328
[TBL] [Abstract][Full Text] [Related]
9. Resistance to natural killer cell lysis conferred by TAP1/2 genes in human antigen-processing mutant cells.
Salcedo M; Momburg F; Hämmerling GJ; Ljunggren HG
J Immunol; 1994 Feb; 152(4):1702-8. PubMed ID: 8120379
[TBL] [Abstract][Full Text] [Related]
10. Qa-1
Zhang X; Sabio E; Krishna C; Ma X; Wang J; Jiang H; Havel JJ; Chan TA
Mol Cancer Res; 2021 Jun; 19(6):1076-1084. PubMed ID: 33674442
[TBL] [Abstract][Full Text] [Related]
11. Systemic deficits in transporter for antigen presentation (TAP)-1 or proteasome subunit LMP2 have little or no effect on tumor incidence.
Johnsen AK; France J; Nagy N; Askew D; Abdul-Karim FW; Gerson SL; Sy MS; Harding CV
Int J Cancer; 2001 Feb; 91(3):366-72. PubMed ID: 11169961
[TBL] [Abstract][Full Text] [Related]
12. Down-regulation of the expression and function of the transporter associated with antigen processing in murine tumor cell lines expressing IL-10.
Salazar-Onfray F; Charo J; Petersson M; Freland S; Noffz G; Qin Z; Blankenstein T; Ljunggren HG; Kiessling R
J Immunol; 1997 Oct; 159(7):3195-202. PubMed ID: 9317117
[TBL] [Abstract][Full Text] [Related]
13. Restoration of the expression of transporters associated with antigen processing in lung carcinoma increases tumor-specific immune responses and survival.
Lou Y; Vitalis TZ; Basha G; Cai B; Chen SS; Choi KB; Jeffries AP; Elliott WM; Atkins D; Seliger B; Jefferies WA
Cancer Res; 2005 Sep; 65(17):7926-33. PubMed ID: 16140964
[TBL] [Abstract][Full Text] [Related]
14. Tapasin-/- and TAP1-/- macrophages are deficient in vacuolar alternate class I MHC (MHC-I) processing due to decreased MHC-I stability at phagolysosomal pH.
Chefalo PJ; Grandea AG; Van Kaer L; Harding CV
J Immunol; 2003 Jun; 170(12):5825-33. PubMed ID: 12794107
[TBL] [Abstract][Full Text] [Related]
15. TAP expression provides a general method for improving the recognition of malignant cells in vivo.
Alimonti J; Zhang QJ; Gabathuler R; Reid G; Chen SS; Jefferies WA
Nat Biotechnol; 2000 May; 18(5):515-20. PubMed ID: 10802618
[TBL] [Abstract][Full Text] [Related]
16. TAP-independent self-peptides enhance T cell recognition of immune-escaped tumors.
Doorduijn EM; Sluijter M; Querido BJ; Oliveira CC; Achour A; Ossendorp F; van der Burg SH; van Hall T
J Clin Invest; 2016 Feb; 126(2):784-94. PubMed ID: 26784543
[TBL] [Abstract][Full Text] [Related]
17. Detection of TAP family dimerizations by an in vivo assay in mammalian cells.
Leveson-Gower DB; Michnick SW; Ling V
Biochemistry; 2004 Nov; 43(44):14257-64. PubMed ID: 15518576
[TBL] [Abstract][Full Text] [Related]
18. Rejection of allogeneic and syngeneic but not MHC class I-deficient tumor grafts by MHC class I-deficient mice.
Freland S; Chambers BJ; Andersson M; Van Kaer L; Ljunggren HG
J Immunol; 1998 Jan; 160(2):572-9. PubMed ID: 9551890
[TBL] [Abstract][Full Text] [Related]
19. Identification of mechanisms underlying transporter associated with antigen processing deficiency in metastatic murine carcinomas.
Setiadi AF; David MD; Chen SS; Hiscott J; Jefferies WA
Cancer Res; 2005 Aug; 65(16):7485-92. PubMed ID: 16103103
[TBL] [Abstract][Full Text] [Related]
20. Cross-presentation of virus-like particles by skin-derived CD8(-) dendritic cells: a dispensable role for TAP.
Ruedl C; Storni T; Lechner F; Bächi T; Bachmann MF
Eur J Immunol; 2002 Mar; 32(3):818-25. PubMed ID: 11870626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
